Board of Directors
Dalton Gooding - Chairman
Mr Gooding was appointed to the Board on 14 November 2002. Mr Gooding, formerly a long-standing partner at Ernst & Young, is a Fellow of the Institute of Chartered Accountants in Australia. Based on over 25 years experience, he is currently a partner of Gooding Pervan and advises to a wide range of businesses with particular emphasis relating to taxation and accounting issues, due diligence, feasibilities and general business advice. Mr Gooding also has a number of other directorships of companies in many different segments of business. Mr Gooding is also a director of other listed companies including Australian Wine Holdings Limited, Brierty Limited, SIPA Resources Limited and Katana Capital Limited.
Jeremy Curnock Cook - Non-executive Director
Mr. Curnock Cook was appointed to the Board on 19 October 2012. Jeremy has served as Chairman of International Bioscience Managers Limited, a corporate and investment advisory firm since 2000, and also currently serves as a director of Excalibur Group Holdings Ltd., a medical sciences investment house. Mr. Curnock Cook is currently on a number of boards of international healthcare and biotechnology companies. Jeremy is the former head of the life science private equity team at Rothschild Asset Management, was responsible for the launch of the first dedicated biotechnology fund for the Australian market and the launch of a joint venture with Johnson & Johnson Development Corporation for the creation of Healthcare Ventures, an investment vehicle dedicated to seed stage investments in Europe, as well as the conception and launch of the International Biotechnology Trust (IBT). Mr. Curnock Cook holds a M.A. in Natural Sciences from Trinity College, Dublin.
Dr William Dolphin Ph.D - CEO and Managing Director
Dr Dolphin was appointed to the Board on 5 March 2008 following completion of the merger with Visiomed Group Limited. Dr Dolphin was previously CEO of Visiomed Group Limited. Dr Dolphin holds a PhD in biophysics obtained from Boston University in 1989. He held appointments as Professor in the Departments of Biomedical Engineering and Biology at Boston University and served as President and Chief Technology Officer of a US-based contract research and development company. Dr Dolphin was subsequently the President, CEO and Chairman of a US medical device company.
In 2003 Dr Dolphin relocated to New Zealand and was CEO of a technology joint venture. Dr Dolphin has served as a director of numerous companies in the US, NZ and Australia, is the author of more than 60 peer-reviewed scientific articles, holds five US and international patents and was twice recipient of the National Research Service Award from the US National Institutes of Health.
Ian Macpherson -Deputy Chairman
Mr Macpherson was appointed to the Board on 5 March 2008 following completion of the merger with Visiomed Group Limited. Mr Macpherson is a graduate from the University of Western Australia with a Bachelor of Commerce (B.Comm). He commenced his career in commerce in 1978 prior to entering the Chartered Accounting profession. In July 1990 he resigned from the partnership of Arthur Anderson and Co to establish the firm of Ord Partners, Chartered Accountants.
Mr Macpherson advises on capital structuring, equity and debt raising, ASIC and Securities Exchange compliance procedures. He is a member of the Institute of Chartered Accountants in Australia. Mr Macpherson is also a director of other listed companies including Navigator Resources Limited and Nimrodel Resources Limited.
Matt McNamara - Non-executive Director
Mr. McNamara was appointed to the Board on 19 October 2012. Matt is currently the Chief Investment Officer and Fund Manager of Bioscience Managers Pty Ltd. He has over 25 years of experience in the healthcare & medical sciences sector. Matt initially worked in molecular biology research and spent 11 years in Sales & Marketing and General Management with Merck & Co. and Johnson & Johnson Medical Pty. Ltd. He has served as SVP Business Development for eBioinformatics Inc., and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty. Ltd.
Dr. Michael S. Perry Ph.D - Non-executive Director
Dr. Perry was appointed to the Board on 6th of February 2013. He currently serves as Vice President and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals Corp. Based in the US and with over 25 years of successful pharmaceutical/biotech management and development experience, Dr. Perry previously served as the Global Head of R&D at Baxter Healthcare; President, Cell & Gene Therapy at Novartis affiliates SyStemix and Genetic Therapy, Inc.; VP Regulatory Affairs at Sandoz Pharmaceuticals Corp; Director of Regulatory Affairs at Schering-Plough Corporation; and Chairman, CEO or CMO at several early stage biotech companies. From 2005 to 2012, Dr. Perry was a Venture Partner with Bay City Capital, a California-based venture capital firm managing over US$1.6 billion invested predominantly in life science companies. Dr. Perry holds a Doctor of Veterinary Medicine, Ph.D. in Biomedical Pharmacology and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. He is a graduate of the International Management Program at Harvard Business School.
Fiona Wood - Non-executive Director
Clinical Professor Wood was re-appointed to the Board on 11 April 2006 following her earlier resignation from the Board on 31 December 2005. Professor Wood is currently Director of the Western Australian Burns Service and a Consultant Plastic Surgeon at both the Royal Perth and Princess Margaret hospitals. She is the Chairman of the McComb Research Foundation established in 1999 with co-founder Marie Stoner.
Clinical Professor Wood has been involved in a number of education and disaster response programs associated with her interest in burns and has published a variety of papers over the years. In addition, she has been the recipient of the 2003 Australian Medical Association "Contribution to Medicine" award and an Order of Australia Medal for her work with Bali bombing victims.
Professor Wood was named West Australian of the Year in 2004 and 2005 and was named as Australian of the Year in 2005.